Athens University Medical School, Psychiatric Clinic, Eginition Hospital, Vas Sophias 74, Athens 11528, Greece.
Eur Psychiatry. 1997;12(7):362-6. doi: 10.1016/s0924-9338(97)80006-5.
The prolactin, cortisol and growth hormone (GH) responses to intravenous administration of 25 mg clomipramine (CMI) were studied in young male psychotic patients who had never received neuroleptics and suffered from schizophrenia (13 patients), delusional disorder (three patients) or schizoaffective disorder (one patient). The test was repeated after 1 month in 16 patients who were hospitalized and treated with haloperidol in doses appropriate for best clinical response (range: 7.5-40 mg daily). Symptomatology was assessed by the Brief Psychiatric Rating Scale (BPRS). There was no association of the side effects caused by the administration of CMI (nausea and emesis) to the GH responses. The side effects appeared significantly less in the after treatment trials. Treatment with haloperidol did not influence the response patterns of the three hormones. An indication that high haloperidol doses may inhibit the prolactin response to CMI was obtained when the data were compared between low (7.5-10 mg/day, mean 9.7) and high (15-40 mg/day, mean 22.0) dose subgroups. Significant positive correlations were found between the prolactin and cortisol responses to CMI in the drug-free state, and the scores in the positive symptoms subscale of the BPRS. The degree of improvement did not correlate to any of the hormonal data.
静脉注射 25 毫克氯米帕明（CMI）后，研究了从未接受过神经阻滞剂且患有精神分裂症（13 例）、妄想障碍（3 例）或分裂情感性障碍（1 例）的年轻男性精神病患者的催乳素、皮质醇和生长激素（GH）反应。16 名住院患者在 1 个月后重复了该测试，这些患者接受了适合最佳临床反应的合适剂量的氟哌啶醇治疗（范围：每日 7.5-40 毫克）。症状通过简明精神病评定量表（BPRS）进行评估。CMI 给药引起的副作用（恶心和呕吐）与 GH 反应之间没有关联。副作用在治疗后试验中明显减少。氟哌啶醇治疗并不影响三种激素的反应模式。当将低剂量（7.5-10 毫克/天，平均 9.7）和高剂量（15-40 毫克/天，平均 22.0）亚组之间的数据进行比较时，获得了高氟哌啶醇剂量可能抑制 CMI 对催乳素反应的迹象。在无药物状态下，CMI 对催乳素和皮质醇的反应与 BPRS 阳性症状子量表的评分之间存在显著的正相关。改善程度与任何激素数据均无关。
